Assoc Prof Lev Kats is a group leader within the Cancer Biology and Therapeutics Program and the co-lead of the Myeloma Medicines theme within the Barrie Dalgleish Centre for Myeloma and Related Blood Cancers. He was awarded his PhD in 2009 from Monash University and completed his post-doctoral training at Beth Israel Deaconess Centre/Harvard Medical School. Assoc Prof Kats is interested in epigenetic regulation, metabolism and targeted therapies and his laboratory uses molecular and functional genomics to develop new treatment strategies for aggressive blood cancers.